# Waypoint Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/waypoint-bio

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.waypointbio.com
- Total disclosed funding: $35M
- Latest round: Series A (May 27, 2026)
- Investors on record: 8

## About

Established in 2021 by Xinchen Wang (CEO) and David Phizicky (CSO), and based in New York, US, Waypoint Bio operates as a developer of tumor cell therapies that focus on cancer and autoimmune diseases using in vivo testing. In May 2026, Waypoint Bio, Inc. raised USD 20 million in series A funding led by Amplify Partners, with participation from General Catalyst Partners, Lux Capital, Mitsui Global Investment, Time BioVentures, Hummingbird Ventures.

Waypoint Bio develops and offers cell therapy design and development with a platform that provides high-throughput, high-dimensional multiplexing screens that leverage spatial biology technology to measure cell-autonomous and non-autonomous effects. Utilizing advances in computer vision, in silico protein design, and pooled screening, Waypoint achieves deep phenotyping and optimized cell therapy selection to create novel cell therapies for solid tumors and autoimmune diseases. 

The company intends to use the May 2026 funding to develop its in vivo cell therapy platform, run tumor-based screening of designs, and advance its programs into clinical testing.

## Funding rounds

- Series A, May 27, 2026, $20M — General Catalyst Partners, Mitsui Global Investment, Hummingbird Ventures, Lux Capital, Amplify Partners, Time BioVentures
- Seed, Jun 28, 2024, $15M — Hummingbird Ventures, Fifty Years, Recode

## Investors

- Hummingbird Ventures (https://capitalatlas.ai/funds/hummingbird-ventures) — Seed, Series A
- Fifty Years (https://capitalatlas.ai/funds/fifty-years) — Seed
- Recode (https://capitalatlas.ai/funds/recode) — Seed
- General Catalyst Partners (https://capitalatlas.ai/funds/general-catalyst-partners) — Series A
- Mitsui Global Investment (https://capitalatlas.ai/funds/mitsui-global-investment) — Series A
- Lux Capital (https://capitalatlas.ai/funds/lux-capital) — Series A
- Amplify Partners (https://capitalatlas.ai/funds/amplify-partners) — Series A
- Time BioVentures (https://capitalatlas.ai/funds/time-bioventures) — Series A